Lv51
1072 积分 2025-09-10 加入
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
6天前
已完结
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
6天前
已完结
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
7天前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
8天前
已完结
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
10天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
10天前
已完结
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
10天前
已完结
A guide to CAR T cell therapies: development, current status and future prospects
13天前
已完结
C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
14天前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
14天前
已完结
皖公网安备34019202002308
